Skip to main content

Predicting the first-in-human (FIH) dose for AAV gene therapy

 Predicting the first-in-human (FIH) dose for AAV gene therapy from non-human primates, such as cynomolgus monkeys (cynos), involves careful extrapolation to ensure safety while aiming for therapeutic efficacy. Cynos are commonly used for AAV studies because of their physiological and immunological similarities to humans, making them an effective model for dose prediction. Here’s a structured approach to predicting the FIH dose for AAV gene therapy based on cyno data:

1. Determining the Relevant Cyno Dose

  • Therapeutic Efficacy Threshold: In cyno studies, a dose that achieves therapeutic efficacy is identified first. For AAV gene therapy, this could mean achieving a target transgene expression level or a specific biomarker change in the target tissue.
  • No Observed Adverse Effect Level (NOAEL): The NOAEL is the highest dose in cynos that does not produce observable adverse effects. It’s crucial to identify this dose to balance efficacy with safety in humans.
  • Maximum Tolerated Dose (MTD): If toxicities are observed at doses above the therapeutic threshold, the MTD helps define the upper limit for safe dosing.

2. Selecting an Appropriate Allometric Scaling Method

To extrapolate from cynos to humans, several allometric scaling methods can be applied:

(a) Body Weight Scaling

  • Method: The dose in vector genomes per kilogram (vg/kg) is scaled directly based on body weight.
  • Formula: DoseHuman=DoseCyno×(WeightHumanWeightCyno)0.67\text{Dose}_{\text{Human}} = \text{Dose}_{\text{Cyno}} \times \left( \frac{\text{Weight}_{\text{Human}}}{\text{Weight}_{\text{Cyno}}} \right)^{0.67}
  • Application: This method is straightforward but may not always fully capture human pharmacokinetics or the biodistribution differences for AAVs.

(b) Body Surface Area (BSA) Scaling

  • Method: BSA scaling is often preferred for gene therapy, as BSA more accurately reflects metabolic scaling across species. For AAV, it may help in approximating systemic exposure and transduction efficiency.
  • Formula: DoseHuman=DoseCyno×(BSAHumanBSACyno)\text{Dose}_{\text{Human}} = \text{Dose}_{\text{Cyno}} \times \left( \frac{\text{BSA}_{\text{Human}}}{\text{BSA}_{\text{Cyno}}} \right)
  • Application: BSA scaling is generally used for biologics and is considered conservative, making it suitable for safety-focused FIH dose predictions.

(c) Physiological Scaling (PBPK Modeling)

  • Method: Physiologically Based Pharmacokinetic (PBPK) modeling incorporates species-specific anatomical, physiological, and biochemical parameters to better predict AAV distribution and clearance. PBPK models often take into account liver function, immune responses, and vector biodistribution.
  • Application: This method is more complex and resource-intensive but can provide a more precise prediction, especially for therapies targeting specific organs or tissues.

3. Adjusting for Immune Responses and Neutralizing Antibodies

  • Pre-existing Immunity: Humans often have pre-existing immunity against AAV serotypes, which can neutralize the vector. Adjustments to the dose may be necessary to ensure enough vector reaches target tissues.
  • Immune Suppression: Some protocols use immune-suppressing regimens to mitigate immune responses, which could impact dose requirements. Immunosuppressive treatments in the cyno model should be carefully considered to match human protocols if used.

4. Applying Safety Factors for FIH Dose Prediction

Given the potential immunogenicity and toxicity risks, a safety factor is applied to the scaled dose to further ensure safety in humans:

  • Conservative Safety Factor (10- to 50-fold): Typically, a 10- to 50-fold safety factor is applied to the NOAEL from cynos, depending on the anticipated risk and uncertainty in dose-response translation.
  • Choosing the Factor: For novel AAV serotypes, high doses, or target organs with higher toxicity risk (like the liver), a higher safety factor is recommended (20- to 50-fold). For more well-characterized AAV vectors with extensive preclinical data, a lower safety factor (10- to 20-fold) may be sufficient.

5. Example Calculation for FIH Dose Prediction

Let’s assume:

  • Efficacy Dose in Cynos: 1 x 10^13 vg/kg
  • NOAEL in Cynos: 5 x 10^13 vg/kg
  • Body Weight of Cyno: ~5 kg
  • Body Weight of Human (Average): ~70 kg
  • Chosen Safety Factor: 10-fold (conservative)

Step 1: Calculate Scaled Human Dose Using Body Weight Scaling

Using the NOAEL as a reference and a scaling factor of 0.670.67:

DoseHuman=5×1013 vg/kg×(705)0.67≈2.92×1014 vg/kg\text{Dose}_{\text{Human}} = 5 \times 10^{13} \, \text{vg/kg} \times \left( \frac{70}{5} \right)^{0.67} \approx 2.92 \times 10^{14} \, \text{vg/kg}

Step 2: Apply Safety Factor

FIH Dose=2.92×1014 vg/kg10=2.92×1013 vg/kg\text{FIH Dose} = \frac{2.92 \times 10^{14} \, \text{vg/kg}}{10} = 2.92 \times 10^{13} \, \text{vg/kg}

Thus, the estimated FIH dose would be 2.92 x 10^13 vg/kg, subject to adjustment based on additional risk factors or immunosuppression protocols.

6. Considerations for FIH Trial Design

  • Dose Escalation: Starting with the conservative FIH dose, a dose-escalation study may follow to identify the therapeutic window.
  • Patient Selection and Monitoring: Pre-screening for anti-AAV antibodies, close monitoring of liver function, and immune responses are critical for patient safety.
  • Endpoints: Assessing early biomarkers, transgene expression levels, and clinical outcomes helps establish a safe and effective dose range.

In conclusion, predicting the FIH dose from cyno data involves carefully balancing efficacy, safety, and immunogenicity considerations, using allometric scaling with an appropriate safety factor to ensure a cautious approach in the FIH trial.

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such as ho
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quantification of si
Read more

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases often r
Read more

Standard Template For Clinical Study Report (CSR)-Gene Therapy

 A Standard Format for a Clinical Study Report (CSR) typically includes the following sections and components: Title Page: Title of the Clinical Study Report Study Title Protocol Number Version Date Sponsor's Name and Logo Date of Report Compilation Table of Contents: A list of all sections, subsections, and appendices with page numbers for easy navigation. List of Abbreviations and Glossary: A compilation of all abbreviations used throughout the report, along with their definitions. Executive Summary: A concise overview of the study, including objectives, methods, key findings, and conclusions. Introduction: Background and rationale for the study. Study objectives and hypotheses. Study Design and Methods: Detailed information about the study design, including: Inclusion and exclusion criteria. Study population and recruitment. Randomization and blinding procedures. Data collection methods and tools. Statistical analysis plan. Ethical Considerations: Information on ethical approval
Read more